High-performance liquid chromatographic determination of (−)-cathinone in plasma

Summary High-performance liquid chromatography (HPLC) for the determination of (–)-cathinone in rabbit and human plasma has been studied. The problem of dimerization during extraction from plasma was satisfactorily resolved. Detection was by UV at 257 nm. Concentration levels as low as 24 ng ml^–1 were satisfactorily determined. This level of sensitivity should be adequate for the detection of (–)-cathinone in the blood of khat users and also for the quantitative determination of (–)-cathinone in blood for pharmacokinetic purposes. The applicability of the assay procedure to pharmacokinetic studies is demonstrated.     

Application of an electrochemical detector to the determination of procarbazine hydrochloride by high-performace liquid chromtography

An amperometric flow-through detector with a carbon paste working electrode was utilized as a high-performance liquid chromatographic (HPLC) detector to determine procarbazine hydrochloride, an antineoplastic agent, in both buffer solution and biological fluids. The HPLC system included an amino-cyano stationary phase and an aqueous (pH 7)-methanolic mobile phase which enabled the separation of procarbazine from its only electroactive degradation product, N-isoprophyl-a- (2-methylhydrazono)-p-toluamide. The electrochemical detector, with an approximate limit of detection of 2 ng procarbazine injected, was 20 times more sensitive to procarbazine than a typical UV detector. The low dead volume (I μl) and superior selectivity of the electrochemical detector enabled the HPLC determination of procarbazine in untreated human urine and plasma.     

A specific HPLC-UV method for the determination of cysteine and related aminothiols in biological samples

We present a highly selective and sensitive method for the determination of cysteine (Cys) and related aminothiols that play important roles in health and disease. The key step in the analysis is treatment with 1,1′-thiocarbonyldiimidazole (TCDI) that rapidly and quantitatively reacts with both the amino and thiol groups to form stable cyclic dithiocarbamates with intense UV absorption. Cys, homocysteine (hCys), and cysteinylglycine in plasma (75 μl), urine (100 μl), or cerebrospinal fluid (100–500 μl) were determined by separating and measuring their cyclic derivatives by a high performance liquid chromatograph (HPLC) connected to a UV detector. The chromatograms obtained using TCDI contained fewer and better-resolved peaks than those produced by less selective reagents used previously. Using chemically similar 2-methylcysteine as the internal standard, high repeatability (variation of less than 5%) and adequate sensitivity to detect small increments (10–20%) in the concentrations of cysteinylglycine and hCys were achieved. The HPLC method can also be modified to measure -penicillamine (greater than 0.8 μM) in plasma (50 μl) providing a potential method to monitor plasma levels of this drug in patients.     

A rapid HPLC method for the determination of carboxylic acids in human urine using a monolithic column

A rapid HPLC method for the determination of carboxylic acids in urine samples using a Chromolith Performance RP/18e 100/4.6 with Chromolith Guard Cartridge RP/18e 10/4.6 (Merck KgaA, Darmstadt, Germany) was developed. The method facilitates the simultaneous determination of aromatic hydrocarbon metabolites mandelic acid (MA) and phenylglyoxylic acid (PGA) from styrene and ethylbenzene, hippuric acid (HA) from toluene and 2-, 3-, 4-methylhippuric acids (MHA) from xylene. 3-Hydroxybenzoic acid (3-HBA) was used as internal standard. A chromatographic run is completed within less than 5 min for styrene, ethylbenzene and toluene metabolites, and within 10 min for xylene metabolites. The detection limits are 9 mg L^–1 urine for MA, 1.25 mg L^–1 urine for PGA, 4.9 mg L^–1 urine for HA, 22 mg L^–1 urine for 2-MHA, and 18.5 mg L^–1 urine for 3-MHA.No significant differences of the MA, PGA and HA concentrations in human urine samples obtained by HPLC chromatography on LiChrosorb RP 18 and on Chromolith RP/18e columns were found. The results were evaluated by using ANOVA.Abbreviations MA mandelic acid - PGA phenylglyoxylic acid - HA hippuric acid - MHA methylhippuric acid - 3-HBA 3-hydroxybenzoic acid - ANOVA analyses of variance - GC gas chromatography - HPLC high-performance liquid chromatography     

Determination of Saccharin in Plasma and Urine by High Performance Liquid Chromatography

Abstract

A sensitive and specific high performance liquid chromatographic (HPLC) assay for the determination of saccharin in plasma and urine was developed. Saccharin is extracted into diethyl ether at acid pH, evaporated, and reconstituted prior to instrumental analysis. Overall recovery of saccharin is 86.9 + 8.6% and the sensitivity limits of detection is 0.15 μg per ml of plasma or urine using a fluorescence detector. The sensitivity limit in plasma can be extended to 20 ng per ml by use of a 2 ml assay volume and detector attenuation. The assay was used for the determination of saccharin in plasma and urine of rats following oral doses of 5 mg/kg.     

Determination of a new calcium antagonist in human plasma by liquid extraction enrichment and HPLC with UV detection

Summary An HPLC method has been developed for the determination of SL 85.1016, a new calcium antagonist arylbenzylamide methylthioether derivative. SL 85.1016 and the internal standard, SL 87.0210, are extracted from alkaline human plasma withn-hexane and back extracted into 0.05 M phosphate buffer (pH 2.5; 0.2 ml). Acetonitrile (50 l) is added to the final aqueous extract in order to prevent absorption of the compounds of interest onto the walls of the glass tube; this solution then is partially processed by HPLC on a C₁₈ column with UV detection (254 nm). The determination limit of the method is 2 ng.ml^–1 of SL 85.1016 in human plasma; the response to the drug is linear in the range 2–200 ng.mg^–1.     

Determination of fosfomycin in human urine by capillary gas chromatography: Application to clinical pharmacokinetic studies

Summary A capillary gas chromatographic method for the determination of fosfomycin in human urine is described. After dilution of the sample and derivatization, analysis was on a HP-1 capillary column and a flame ionization detector was used to determine the bistrimethylsilyl derivative of fosfomycin. Response was linear in the range 50–5000 g mL^–1. The detection limit was about 10 g mL^–1. The within and between day coefficients of variation did not exceed 6%. The method was applied to the determination of fosfomycin in urine samples collected during clinical pharmacokinetic studies.     

Multiresidue analysis of phenylurea herbicides in environmental waters by capillary electrophoresis using electrochemical detection

A rapid multiresidue method has been developed for the analysis of seven phenylurea herbicides in the presence of two s-triazines in environmental waters. A simple end-column electrochemical detector was used in combination with a commercially-available capillary electrophoresis instrument with UV detection. The determination of phenylurea pesticides using micellar electrokinetic capillary chromatography with electrochemical detection represents the first such determination that has been reported. In both detection systems, linear ranges were obtained for the seven phenylurea herbicides at concentrations lower than 2.0×10^–5 mol l^–1, in 0.020 mol l^–1 phosphoric acid at pH 7.0 and containing 0.020 mol l^–1 of sodium dodecylsulfate, in order to obtain selectivity in the additional separation by a micellar distribution process. Under these conditions a detection limit lower than 5.0×10^–6 mol l^–1 (0.25 pmol of pesticide) was achieved for most of them. The pesticides were resolved in less than 30 min.     

Determination of uric acid in human saliva by capillary electrophoresis with electrochemical detection: potential application in fast diagnosis of gout

The clinical manifestations of gout result from the formation and deposition of uric acid (UA) crystals. The monitoring of UA level in less invasive biological samples such as saliva is suggested for diagnosis and therapy of gout, hyperuricemia and the Lesch–Nyhan syndrome. In order to investigate the correlation between trace amounts of UA in human saliva and urine and explore the potential application in fast diagnosis of gout, capillary electrophoresis with electrochemical detection (CE–ED) was applied for the determination of UA in human saliva and urine in this work. Under the optimum conditions, UA and three coexisting analytes could be well separated within 14 min at the separation voltage of 14 kV in 80 mmol L^–1 borax running buffer (pH 7.8). A good linear relationship was established between peak current and concentration of analytes over two orders of magnitude with detection limits (S/N=3) ranging from 1.09×10^–7 to 5.0×10^–7 mol L^–1 for all analytes. This proposed method has been successfully applied for study of the correlation between the UA content of human saliva and urine, providing an alternative and convenient method for rapid diagnosis of gout.     

Determination of nifedipine in human plasma by high performance liquid chromatography using column-switching technique

A highly sensitive reversed-phase HPLC method has been developed for the determination of nifedipine in human plasma with electrochemical detection. A liquid-liquid extraction procedure is used in sample preparation with an average extraction recovery of 75%. Removing the highly lipophilic plasma components using a special column switching technique reduced the duration of the HPLC measurement from 30 to 9 min. The method is applicable for the pharmacokinetic characterization and bioavailability study of a sustained-release (retard) formulation of nifedipine and for human drug monitoring as it is indicated by the validation of the analysis method. The assay gave a linear response over the concentration range 2.5–50 ng/ml. All the validation parameters are within the internationally required limits.     

Determination of highly polar compounds in water samples around former ammunition plants

Summary A method was developed for the determination of nitrobenzoic acids and nitrophenols as well as of diaminoaromatics and was applied to the analysis of water samples from the former ammunition plant at Elsnig (Saxony, Germany). The procedure is based on a preseparation into a neutral, an acidic and a basic fraction by multi-step extraction at different pH values followed by HPLC analysis with UV and electrochemical detectors, coupled in series. Applying optimized enrichment conditions, all investigated compounds were extracted from spiked distilled water with recoveries >80% and variation coefficients <7%. Similar results were obtained with spiked ground water samples. After enrichment, all compounds can be analysed by HPLC with UV detection at concentrations below 100 ngL⁻¹. The electrochemical detector (ELCD) allowed a selective and sensitive detection of the nitrophenols and especially of the diaminoaromatics and, therefore, provides, some advantages in the analysis of real samples. Presented at the 21^st ISC held in Stuttgart, Germany, 15^th–20^th September, 1996     

HPLC Determination of Imidazoles with Variant Anti-Infective Activity in Their Dosage Forms and Human Plasma

A suitable HPLC method has been selected and validated for rapid simultaneous separation and determination of four imidazole anti-infective drugs, secnidazole, omeprazole, albendazole, and fenbendazole, in their final dosage forms, in addition to human plasma within 5 min. The method suitability was derived from the superiority of using the environmentally benign solvent, methanol over acetonitrile as a mobile phase component in respect of safety issues and migration times. Separation of the four anti-infective drugs was performed on a Thermo Scientific^® BDS Hypersil C₈ column (5 µm, 2.50 × 4.60 mm) using a mobile phase consist of MeOH: 0.025 M KH₂PO₄ (70:30, v/v) adjusted to pH 3.20 with ortho-phosphoric acid at room temperature. The flow rate was 1.00 mL/min and maximum absorption was measured with UV detector set at 300 nm. Limits of detection were reported to be 0.41, 0.13, 0.18, and 0.15 µg/mL for secnidazole, omeprazole, albendazole, and fenbendazole, respectively, showing a high degree of the method sensitivity. The method of analysis was validated according to Food and Drug Administration (FDA)guidelines for the determination of the drugs, either in their dosage forms with highly precise recoveries, or clinically in human plasma, especially regarding pharmacokinetic and bioequivalence studies.     

An electromembrane extraction–HPLC‐UV analysis for the determination of valproic acid in human plasma

In this study, an electromembrane extraction (EME) method combined with a simple HPLC‐UV analysis was developed and validated for the determination of valproic acid in human plasma samples. The major parameters influencing EME procedure, namely the solvent composition, voltage, pH of acceptor and donor solutions, salt effect, and time of extraction, were evaluated and optimized. The drug was extracted from the donor aqueous sample solution (pH 5) to the acceptor aqueous solution (pH 13). The donor and acceptor phases were separated by a hollow fiber dipped in 1‐octanol as a supported liquid membrane. A voltage of 60 V during 25 min was applied as the driving force. The drug concentration enrichment factor obtained was >125, which enhanced the sensitivity of the method. The limit of detection and the limit of quantitation were 0.2 and 0.5 μg/mL, respectively. The proposed method was successfully applied to a human plasma sample, with a relative recovery of 75%. The method was linear over the range 0.5–10 μg/mL for valproic acid (R² > 0.9996) with a repeatability (%RSD) between 0.9 and 3.3% (n = 3). Valproic acid is an anticonvulsant drug with poor UV absorption, and EME can improve the sensitivity of HPLC‐UV for the determination of valproic acid in plasma samples.     

HPLC for stress-free screening of potential prostate cancer marker catechol estrogens in urine using a diamond-electrode electrochemical and a fluorescence detector

Improvement of the sensitivity and specificity of a simultaneous stress-free screening method for catechol estrogens as a potential prostate cancer marker in urine has been accomplished by HPLC with a diamond-electrode electrochemical detector and a fluorescence detector. Since taking urine samples generates less stress (or pain) than the drawing of blood, the method can readily be applied to almost any patient, and will also assist in improving the sensitivity and specificity of the prostatic specific antigen test. Catechol estrogens (2-hydroxyestrone, 4-hydroxyestrone, 2-methoxyestrone, 2-hydroxyestradiol, 4-hydroxyestradiol, 2-methoxyestradiol, and 2-hydroxyestriol) and estrogens (estrone, estradiol, estriol) were separated on an Inertsil ODS-II column with acetonitrile-potassium dihydrogen phosphate (pH 3.0). The diamond-electrode electrochemical detector used had the great advantage of being a maintenance-free system, and could sequentially analyze hundreds of samples. Fluorescence detection improved the sensitivity 10-500 times (e. g., the LOD of 2-hydroxyestriol was improved 250 times) compared to previous electrochemical detection reports, and dual detection improved peak identification in the urine samples. The proposed method was applied to the simultaneous determination of catechol estrogens in spiked urine in a preliminary study on estrogens and PSA values in biopsy and prostate cancer patients.     

Determination of imipenem (N-formimidoyl thienamycin) in human plasma and urine by high-performance liquid chromatography, comparison with microbiological methodology and stability

High-performance liquid chromatographic (HPLC) methods using ultraviolet (UV) detection have been developed for the assay of the antibiotic imipenem (N-formimidoyl thienamycin) in human plasma and urine. A reversed-phase analytical column is employed in the plasma assay method and a cation-exchange column is used in the urine assay method. Both methods use borate buffer in the mobile phase. The method of preparation of human fluid samples for HPLC injection has been optimized with respect to the stability of imipenem in aqueous buffers, in morpholine buffer--ethylene glycol stabilizer, and in urine and plasma. Preparation of the samples before injection into the HPLC systems involves deproteination/filtration of the plasma/urine samples. The open lactam metabolite and the coadministered dehydropeptidase inhibitor, cilastatin sodium, do not interfere with the 313-nm detection of imipenem in either the plasma or the urine assay. Thienamycin, the precursor of imipenem and an impurity in imipenem formulations, is separated from the drug using both of these methods. Concentrations generated from the HPLC analysis of plasma and urine samples from two healthy volunteers compare favorably with results using a microbiological assay method. Correlation of the two methods gives r greater than or equal to 0.990 for both fluids.     

Micelle-Enhanced Spectrofluorimetric Method for the Determination of Antibacterial Trovafloxacin in Human Urine and Serum

A spectrofluorimetric method for the determination of trace amounts of the antibacterial trovafloxacin has been developed based on its native fluorescence in a micellar solution of sodium dodecyl sulfate (SDS). The wavelengths of excitation and emission were 270 nm and 410 nm, respectively. The optimised method allows the determination of 3.0–40.0 ng mL⁻¹ of trovafloxacin in 8 mM SDS solution and 0.1 M acetic acid-sodium acetate buffer solution (pH 5.5), with a relative standard deviation of 1.5% (for a level of 12.0 ng mL⁻¹) and a detection limit of 0.8 ng mL⁻¹. The method was applied to the determination of trovafloxacin in human urine and serum samples. It was validated using HPLC as a reference method. Recovery levels of the method reached 100% in all cases.     

Pre-column derivatization of rofecoxib for determination in serum by HPLC

An HPLC method for determination of rofecoxib in human serum is presented. The method is based on pre-column derivatization of analyte to a phenanthrene derivative of the drug. Rofecoxib and the internal standard were extracted from serum using liquid–liquid extraction. Upon exposure to UV light, the drug was found to undergo a photocyclization reaction, giving a species with high absorbance. Validation of the method has been studied in the concentration range 10–500 ng ml^–1.     

Development and validation of a novel HPLC/ELSD method for the direct determination of tobramycin in pharmaceuticals,plasma, and urine

A novel method for the direct determination of the aminoglycoside tobramycin was developed and validated based on reversed-phase high-performance liquid chromatography (RP-HPLC) with evaporative light scattering detector (ELSD). Using a Waters ODS-2 C18 Spherisorb column with an evaporation temperature of 45°C and nitrogen pressure of 3.5 bar, the selected mobile phase consisted of water/acetonitrile 55:45 containing 1.5 mL L^–1 HFBA (11.6 mM) in an isocratic mode at a rate of 1.0 mL min^–1. Tobramycins retention time was 4.3 min with an asymmetry factor of 1.7. A logarithmic calibration curve was obtained from 1 to 38 g mL^–1 (r > 0.9998). LOD was 0.3 g mL^–1; within-day %RSD was 1.0 (n = 3, 4.7 g mL^–1) and between-day %RSD was 1.1 (3 days within a week). The developed method was applied to the determination of tobramycin in a pharmaceutical crude substance and formulations (eye drops and ointments). Dilution experiments revealed the absence of interference from excipients (no constant and proportional errors); recovery from spiked samples was 99–103% with %RSD < 2.2 (n = 3×3). The developed HPLC/ELSD method was also found to be applicable in the determination of tobramycin in human plasma (0.6–12.5 g mL^–1) and urine (1.5–12.5 g mL^–1) after solid-phase extraction using carboxylate cartridges followed by solvent evaporation (×2 preconcentration). A mean recovery of 86% for plasma and 91% for urine was obtained.     

Determination of cabergoline in plasma and urine by high-performance liquid chromatography with electrochemical detection.

A sensitive and selective high-performance liquid chromatographic method for the determination of cabergoline in plasma and urine has been developed. After buffering plasma and urine samples, cabergoline was extracted with a methylene chloride-isooctane mixture, back-extracted into 0.1 M phosphoric acid, then analysed by reversed-phase high-performance liquid chromatography. Quantitation was achieved by electrochemical detection of the eluate. The linearity, precision and accuracy of the method were evaluated. No interference from the biological matrices (human plasma and urine) was observed. The assay was still inadequate in terms of sensitivity for the quantitation of cabergoline plasma concentrations after a single oral dose of 1 mg of the drug to humans, but was successfully used in the determination of the urinary excretion of the drug.     

Isolation of new quinidine metabolites and simultaneous determination of quinidine and its metabolites in blood and urine by direct injection HPLC analysis

Summary New quinidine metabolites, including 10,11-dihydrodiol quinidine N-oxide, 10,11-dihydrodiol quinidine and their glucuronides, were found in human urine. A quinidine monitoring HPLC method including these metabolites, is proposed by the direct injection of body fluid samples onto the precolumn for deproteinization followed by reverse phase separation in the analytical column with a column switching technique. The recovery of spiked quinidine and its metabolites in plasma was quantitative (98–102%) with good reproducibility (C.V.: 1.6–4.0%). Several clinical samples such as whole blood and urine were analyzed by the present method.